LeMaitre Vascular, Inc. LMAT
LeMaitre Vascular, Inc. (Nasdaq: LMAT) is a cardio-renal-metabolic medical device company. Its next catalyst on record is RestoreFlow allografts: Commence allograft distribution in Ireland (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: RestoreFlow allografts — Commence allograft distribution in Ireland (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Artegraft bovine vascular graft (pre-amendment Class III; CE mark April 2025) | Vascular access/bypass | — | NA_NON_THERAPEUTIC |
| XenoSure patch - China NMPA vascular indication application | Vascular repair | — | NA_NON_THERAPEUTIC |
| RestoreFlow allografts (Germany cryopreservation began May 2026; Ireland distribution planned) | Vascular and cardiac tissue | — | NA_NON_THERAPEUTIC |
| PhasTIPP powered phlebectomy system | Varicose veins | — | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other cardio-renal-metabolic companies
- DexCom, Inc. DXCM
- Penumbra Inc PEN
- Insulet Corp PODD
- MiniMed Group, Inc. MMED
- Heartflow, Inc. HTFL
- iRhythm Holdings, Inc. IRTC
- Pulse Biosciences, Inc. PLSE
- AtriCure, Inc. ATRC
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.